Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma
2009; Wiley; Volume: 85; Issue: 1 Linguagem: Inglês
10.1002/ajh.21571
ISSN1096-8652
AutoresGaetano Corazzelli, Rosaria De Filippi, Gaetana Capobianco, Ferdinando Frigeri, Vincenzo De Rosa, Giancarla Iaccarino, Filippo Russo, Manuela Arcamone, Cristina Becchimanzi, Stefania Crisci, Gianpaolo Marcacci, Barbara Amoroso, Secondo Lastoria, Antonio Pinto,
Tópico(s)CNS Lymphoma Diagnosis and Treatment
ResumoAmerican Journal of HematologyVolume 85, Issue 1 p. 87-90 LettersFree Access Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma† Gaetano Corazzelli, Gaetano Corazzelli Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy Gaetano Corazzeli and Rosaria De Fillippi contributed equally to the studySearch for more papers by this authorRosaria De Filippi, Rosaria De Filippi Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy Department of Cellular and Molecular Biology and Pathology, Faculty of Biotechnological Sciences, Federico II University, Naples, Italy Gaetano Corazzeli and Rosaria De Fillippi contributed equally to the studySearch for more papers by this authorGaetana Capobianco, Gaetana Capobianco Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorFerdinando Frigeri, Ferdinando Frigeri Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorVincenzo De Rosa, Vincenzo De Rosa Radiology Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorGiancarla Iaccarino, Giancarla Iaccarino Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorFilippo Russo, Filippo Russo Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorManuela Arcamone, Manuela Arcamone Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorCristina Becchimanzi, Cristina Becchimanzi Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorStefania Crisci, Stefania Crisci Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorGianpaolo Marcacci, Gianpaolo Marcacci Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorBarbara Amoroso, Barbara Amoroso The Binding Site, Rome, ItalySearch for more papers by this authorSecondo Lastoria, Secondo Lastoria Nuclear Medicine Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorAntonio Pinto, Corresponding Author Antonio Pinto [email protected] Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalyHematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola, I-80131, Naples, ItalySearch for more papers by this author Gaetano Corazzelli, Gaetano Corazzelli Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy Gaetano Corazzeli and Rosaria De Fillippi contributed equally to the studySearch for more papers by this authorRosaria De Filippi, Rosaria De Filippi Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, Italy Department of Cellular and Molecular Biology and Pathology, Faculty of Biotechnological Sciences, Federico II University, Naples, Italy Gaetano Corazzeli and Rosaria De Fillippi contributed equally to the studySearch for more papers by this authorGaetana Capobianco, Gaetana Capobianco Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorFerdinando Frigeri, Ferdinando Frigeri Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorVincenzo De Rosa, Vincenzo De Rosa Radiology Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorGiancarla Iaccarino, Giancarla Iaccarino Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorFilippo Russo, Filippo Russo Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorManuela Arcamone, Manuela Arcamone Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorCristina Becchimanzi, Cristina Becchimanzi Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorStefania Crisci, Stefania Crisci Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorGianpaolo Marcacci, Gianpaolo Marcacci Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorBarbara Amoroso, Barbara Amoroso The Binding Site, Rome, ItalySearch for more papers by this authorSecondo Lastoria, Secondo Lastoria Nuclear Medicine Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalySearch for more papers by this authorAntonio Pinto, Corresponding Author Antonio Pinto [email protected] Hematology-Oncology and Stem Cell Transplantation Unit, Department of Hematology, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Naples, ItalyHematology-Oncology and Stem Cell Transplantation Unit, National Cancer Institute, Fondazione 'G. Pascale', IRCCS, Via Mariano Semmola, I-80131, Naples, ItalySearch for more papers by this author First published: 21 October 2009 https://doi.org/10.1002/ajh.21571Citations: 10 † Conflict of interest: B.A. acts as a consultant to the Binding Site. All other authors declare no competing financial interests. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Brice P. Managing relapsed and refractory Hodgkin lymphoma. Br J Haematol 2008; 141: 3– 13. 2 Chanan-Khan AA,Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008; 26: 1544– 1552. 3 Kuppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9: 15– 27. 4 Verhelle D,Corral LG,Wong K, et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007; 67: 746– 755. 5 Cheson BD,Pfistner B,Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579– 586. 6 Tecchio C,Nadali G,Scapini P, et al. High serum levels of B-lymphocyte stimulator are associated with clinical-pathological features and outcome in classical Hodgkin lymphoma. Br J Haematol 2007; 137: 553– 559. 7 Pratt G. The evolving use of serum free light chain assays in haematology. Br J Haematol 2008; 141: 413– 422. 8 Ferrajoli A,Lee BN,Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291– 5297. 9 Andritsos LA,Johnson AJ,Lozanski G, et al. Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 2519– 2525. 10 Chanan-Khan A,Miller KC,Musial L, et al. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 2006; 24: 5343– 5349. 11 Chanan-Khan AA,Whitworth A,Bangia N, et al. Lenalidomide-associated tumor flare reaction is manageable in patients with chronic lymphocytic leukemia. J Clin Oncol 2008; 26: 4851– 4852. 12 Borchmann P,Topp M,Reiners K, et al. Early report on the activity of lenalidomide in chemotherapy-refractory Hodgkin lymphoma patients. Ann Oncol 2008; 19 ( Suppl. 4): iv167. 13 Fehniger TA,Larson S,Trinkaus K, et al. A phase II multicenter study of lenalidomide in patients with relapsed or refractory classical Hodgkin lymphoma (cHL): Preliminary results. Blood 2008; 112: 2595 (ASH Annual Meeting Abstracts). 14 Kuruvilla J,Taylor D,Wang L, et al. Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin Lymphoma. Blood 2008; 112: 3052 (ASH Annual Meeting Abstracts). 15 Thio M,Blokhuis BR,Nijkamp FP,Redegeld FA. Free immunoglobulin light chains: A novel target in the therapy of inflammatory diseases. Trends Pharmacol Sci 2008; 29: 170– 174. Citing Literature Volume85, Issue1January 2010Pages 87-90 ReferencesRelatedInformation
Referência(s)